

A clinical in-hospital prognostic score for acute exacerbations of COPD

Nicolas Roche, Jean-Michel Chavaillon, Cyril Maurer, Mahmoud Zureik,
Jacques Piquet

► **To cite this version:**

Nicolas Roche, Jean-Michel Chavaillon, Cyril Maurer, Mahmoud Zureik, Jacques Piquet. A clinical in-hospital prognostic score for acute exacerbations of COPD. *Respiratory Research*, BioMed Central, 2014, 15, pp.99. <inserm-01098208>

HAL Id: inserm-01098208

<http://www.hal.inserm.fr/inserm-01098208>

Submitted on 23 Dec 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access

A clinical in-hospital prognostic score for acute exacerbations of COPD

Nicolas Roche^{1*}, Jean-Michel Chavaillon², Cyril Maurer³, Mahmoud Zureik⁴ and Jacques Piquet³

Abstract

Background: The use of a severity score to help orientation decisions could improve the efficiency of care for acute exacerbations of COPD (AECOPD). We previously developed a score ('2008 score', based on age, dyspnea grade at steady state and number of clinical signs of severity) predicting in-hospital mortality in patients with AECOPD visiting emergency departments (EDs). External validity of this score remained to be assessed.

Objectives: To test the predictive properties of the '2008 score' in a population of patients hospitalized in medical respiratory wards for AECOPD, and determine whether a new score specifically derived from this population would differ from the previous score in terms of components or predictive performance.

Methods: Data from a cohort study in 1824 patients hospitalized in a medical ward for an AECOPD were analyzed. Patients were categorized using the 2008 score and its predictive characteristics for in-hospital mortality rates were assessed. A new score was developed using multivariate logistic regression modeling in a randomly selected derivation population sample followed by testing in the remaining population (validation sample). Robustness of results was assessed by case-by-case validation.

Results: The 2008 score was characterized by a c-statistic at 0.77, a sensitivity of 69% and a specificity of 76% for prediction of in-hospital mortality. The new score comprised the same variables plus major cardiac comorbidities and was characterized by a c-statistic of 0.78, a sensitivity of 77% and specificity of 66%.

Conclusions: A score using simple clinical variables has robust properties for predicting the risk of in-hospital death in patients hospitalized for AECOPD. Adding cardiac comorbidities to the original score increased its sensitivity while decreasing its specificity.

Keywords: Acute exacerbation, Prognosis, Score, Pulmonary Disease, Chronic Obstructive

Introduction

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are major events in the long-term course of the disease since their repetition is associated with impaired lung function, health status and survival and markedly increased health care costs [1]. On the short-term, they impair often notably health status and expose to risks of acute respiratory failure and death. Home-based care has been shown to represent a valuable alternative for many patients visiting emergency departments (EDs), allowing to avoid or shorten hospital stays [2]. However, most patients with AECOPD visiting EDs are hospitalized. In that context, assessing the

severity of AECOPD is mandatory to guide decisions of orientation (home, hospital medical ward or intensive care unit -ICU-) as well as intensity of monitoring, treatment and follow-up during and after the acute episode [3]. Knowledge of all relevant prognostic factors is of major importance to determine the safest and most cost-effective setting for patient care. Several scores (e.g., the BAP-65 or DECAF scores) have been specifically developed to allow risk prediction in patients hospitalized for acute exacerbations of COPD, and were shown to perform better than scores primarily developed for other respiratory illnesses (i.e., community-acquired pneumonia) such as CURB-65 [4,5]. However, studies in this area are heterogeneous in terms of measured variables. In addition, some data (such as biomarkers) [6] might not be readily available in all settings, underlining the need for simple, purely clinical prediction rules. In other diseases such as

* Correspondence: nicolas.roche@cch.aphp.fr

¹Respiratory and Intensive Care Medicine department, Cochin Hospital Group, APHP, University Paris Descartes (EA2511), 75005 Paris, France
Full list of author information is available at the end of the article

community-acquired pneumonia, the use of scores (e.g., the Pneumonia Severity Index) was shown to improve the efficiency of care by allowing to decrease hospitalization rates without increasing the risk of poor outcome [7].

In 2003–2004, we conducted a prospective cohort study of 794 patients with AECOPD recruited in 104 French emergency departments [8]. Among these patients, only 10.5% were discharged home; in the remaining, the in-hospital mortality rate was 7.4%. Independent predictors of in-hospital death were age, clinical signs of severity and baseline dyspnea grade at steady state. From these observations, we derived and validated a prognostic score (Table 1) using two randomly selected halves of the cohort (the derivation and validation cohorts). For convenience, this score will be subsequently called the ‘2008 score’ after its year of publication. Its discriminative capacity proved to be satisfactory with a c-statistic (which is analogous to the area under the receiver operating characteristic -ROC-curve) at 0.82 in the validation cohort. Therefore, we aimed at assessing the validity of the 2008 score in another cohort that was primarily built to assess the long-term (4 years) prognosis and prognostic factors of patients hospitalized in medical wards for an AECOPD [9]. Considering the marked differences in the mode of recruitment (hospital wards vs EDs), study period, patients’ characteristics and mortality rate (see Table 2) between the two cohorts, we postulated that demonstrating a satisfactory discriminative capacity of the 2008 score in this new cohort would allow to generalize its use.

We also questioned whether a new score developed using data from patients of the new cohort would be different and more accurate to predict prognosis than the 2008 score. Thus, we applied the same methodology as in the previous study to develop a new score before

Table 1 Calculation of the 2008 score

2008 score	Points
Age	
• < 70 years	0
• ≥ 70 years	1
MRC (baseline, steady state)	
• 0-1	0
• 2-3	1
• 4-5	2
Number of signs of severity* at entry	
• 0	0
• 1-2	2
• 3 and more	3

*signs of severity: cyanosis, use of accessory inspiratory muscles, paradoxical abdominal movement, asterixis, neurological impairment, lower limb edema. Total score ranges from 0 to 6. Tertiles of the original (2008) population corresponded to scores of 0–1, 2–3 and 4–6, respectively.

Table 2 Main differences between the population in which the 2008 score was developed and the present population. All $p \leq 0.001$

Variable	Present population	2008 population
Sex, % women	23.2	30.0
Age (years, mean ± SD)	70.3 ± 11.3	72.5 ± 11.8
Smoking status, %		
• Non smoker	6.6	19.3
• Ex smoker	60.8	49.9
• Smoker	32.6	30.8
MRC dyspnea grade at steady state, %		
• 0/1	17.1	22.5
• 2-3	69.9	46.2
• 4	13.0	31.3
Maintenance treatment, %		
• LTOT	37.7	23.2
• Inhaled corticosteroids	72.4	43.8
• Oral corticosteroids	7.8	13.8
• Bronchodilators	86.6	69.6
Clinical signs of severity, %		
• Cyanosis	22.1	29.0
• Use of accessory inspiratory muscles	27.9	50.9
• Paradoxical abdominal movement	8.6	36.8
• Asterixis	1.8	7.8
• Neurological impairment	6.9	11.8
• Lower limb edema	13.3	23.3
Number of clinical signs of severity, %		
• None	44.1	27.6
• 1 -2	45.9	47.7
• ≥ 3	10.0	24.7
Mortality (%)	2.5	7.9

comparing its components and performance to that of the 2008 score.

Material and methods

Study design

Details on study design and collected data have been published previously [9,10]. From October 2006 to June 2007, lung specialists from 68 French general hospitals consecutively included 1,824 patients newly admitted in their respiratory medicine department for an acute exacerbation of COPD, regardless of the source of admission (i.e., direct referral or via emergency department, intensive care unit [ICU], outpatient clinic, or another department or hospital). To be selected patients had to satisfy four conditions: (1) having or being strongly suspected of having COPD; for the second category, i.e. those suspected of

having COPD, the diagnosis had to be confirmed subsequently by senior lung specialists during hospital stay; (2) presenting with an acute increase in at least one cardinal respiratory symptom (cough, sputum production or purulence, dyspnea) that was not immediately attributable to an alternative diagnosis such as pulmonary edema, pulmonary embolism, etc.; and (3) presenting with a condition considered sufficiently worrying in terms of duration and intensity to warrant hospitalization. All patients were informed of the objectives and requirements of the study and gave their oral consent before inclusion, as required by French regulation on observational studies. The protocol was approved by the Ethics Committee of the French-Language Society of Pulmonology.

Collected data

Collected data addressed the characteristics of (i) the patient (i.e., anthropometric and sociodemographic characteristics, medical history, habits); (ii) underlying COPD (clinical characteristics, FEV₁ and management before the exacerbation); (iii) the acute exacerbation (etiology and clinical characteristics on admission); (iv) hospital care (admission modalities, care pathways, treatments of the acute exacerbation) and (v) outcomes (duration of hospital stay, vital status at discharge). Spirometry results used in the analyses were the most recent prior to the exacerbation. Collected comorbidities of interest were ischemic heart disease, left heart failure, pulmonary hypertension, gastro-esophageal reflux, lung cancer, associated respiratory diagnoses (asthma, bronchiectasis, sleep apnea syndrome, obesity-hypoventilation syndrome).

Statistical analyses

Standard SAS[®] procedures (SAS Institute, Cary, NC, USA) were used for statistical analysis. A description of the population was performed for all variables. Characteristics of this population were compared to that of the 2008 population using Chi²-test for categorical variables and Student t test or analysis of variance (ANOVA) (normal distribution) or non-parametric tests (non-normal distribution) for quantitative variables. The same methods were used to analyze factors associated with in-hospital death in the present population.

Two approaches were then used to test the validity of the 2008 score: the first was its implementation in the present population, allowing to calculate mortality rates by score category and to assess its predictive properties; the second was the development of a new score based on the characteristics of the present population, to assess whether this new score would be different from the 2008 score in terms of components and predictive performance.

Application of the 2008 score in the studied population

To assess the global predictive capacity of the 2008 score in the present population, the score was calculated for each patient and the population was divided into three groups based on the scores observed in tertiles of the 2008 population (i.e., 0–1 for group 1, 2–3 for group 2 and 4 or more for group 3). Mortality rates were compared between groups, and sensitivity and specificity of the score for prediction of mortality was assessed. The c-statistic, which is analogous to the area under the receiver operating characteristic (ROC) curve, was then calculated.

Development of a new score

To develop the new score, we used data collected during the first 24 hours of hospitalization in the studied population (see above). Two methods were used: the first (described below) was based on randomly selected derivation and validation cohorts, as for the development of the 2008 score, while the second (presented in the online Additional file 1) used score derivation and case-by-case validation in the whole population.

To implement the first method, the population was randomly split into two groups: a derivation cohort (n = 912) and a validation cohort (n = 912). In the derivation cohort, a backward stepwise logistic regression procedure was used, in which variables that were significant at p < 0.25 in univariate analyses were introduced. This p-value threshold was chosen to ensure without any doubt that no relevant variable would be missed: indeed, some variables that were thought to be of potential clinical importance such as coexisting asthma or sleep apnea syndrome were associated with mortality with a p value of about 0.20 in univariate analysis. Variables were eligible for inclusion in the final model if they were significantly associated with death at a two-tailed p-value of less than 0.05. As previously described [11–13], the multivariate model then allowed developing a point-based risk scoring system: the number of points assigned to each risk factor was obtained by dividing each Beta coefficient by the smallest Beta coefficient significantly different from 0 and rounding to the nearest integer. A risk score was assigned to each participant in both derivation and validation cohorts by summing the number of points corresponding to each risk factor. Model discrimination was assessed by the c statistic. In both derivation and validation cohorts, subjects were divided into three groups corresponding to tertiles of the score in the whole population, and mortality rates were compared between groups.

Results

Patients and in-hospital outcomes

Recruited patients reported recent acute and sustained onset or increase in dyspnea in 95% of cases, cough in

65% and sputum volume and/or purulence in 55%. Table 2 shows the main characteristics of the 1,824 patients at entry, compared to the 2008 population. Age was <60 years in 19.9% and ≥80 years in 23.2%. There was no difference in cumulative smoking (43.5 ± 25.2 vs 46.4 ± 30.0 pack-years), percentage of patients complaining of an increase in dyspnea (95.2% vs 99.2%) or of purulent sputum (42.6% in each population), percentage of patients in whom COPD had been previously diagnosed (84.1% vs 84.6%). Only 6.6% of patients were never smokers, 32.6% were still active smokers. Lung function data were obtained for 1615 patients (88.9%), with a delay of 17.4 ± 23.9 months between spirometry and hospital admission for AECOPD. FEV₁ was 45.6 ± 17.7 L/s, with the following distribution of GOLD severity of airflow obstruction: GOLD I: 4.5%; GOLD II: 32.7%; GOLD III: 43.5%; GOLD IV: 19.4%. This could not be compared to the 2008 population, in which lung function data were not available in most cases in the context of the Emergency Department setting. Comorbidities, which were not recorded in details in the 2008 population either, were frequent in the present population: ischemic heart disease (IHD): 19.0%, left heart failure (LHF): 12.7%, systemic hypertension: 35.1%, asthma: 13%. BMI was ≤20 kg/m² in 20.3% of patients and >25 kg/m² in 45.1%.

In-hospital mortality rate was 2.46% (n = 45). Hospital length of stay was 12.1 ± 9.7 days, i.e., similar to what was observed in the 2008 population (11.8 ± 14.1 days).

Application of the 2008 score

Patients were distributed in three groups based on their 2008 score. These groups were defined based on the tertiles of the score in the original (2008) population. Mortality rates are shown in Table 3, and Table 4 presents the discriminative performance of the score, which was characterized by a c-statistic at 0.77, with a sensitivity of 69% and a specificity of 76%. In Tables 3 and 4, these results are compared to that obtained with the new score (see below).

Development of the new score

Variables associated with survival status at the end of hospital stay in univariate analyses performed in the

whole studied population are presented in Additional file 1: Tables S1 and S2. Among these, multivariate analyses in the derivation cohort identified age, number of clinical signs of severity, mMRC dyspnea grade at steady state and presence of cardio-vascular comorbidities (ischemic heart disease and/or left heart failure) as being independently associated with mortality (Table 5). Table 6 shows how the new score was calculated based on these results. Mortality rates in the three tertiles of the score are shown in Table 3 for the derivation and validation cohorts, compared to those observed with the 2008 score in the three groups of the whole studied population defined with reference to distribution (i.e., tertiles) of this score in the 2008 population. The discriminative performance of the new score in the derivation and validation cohorts is presented in Table 4, compared to that of the 2008 score. The c-statistics were at 0.79 and 0.78 in the derivation and validation cohorts, respectively, with a sensitivity of 77% in both cohorts and specificities of 67% and 66%, respectively. Results of the case-by-case development and validation method were identical and are presented in Additional file 1: Table S3.

Discussion

The initial score published in 2008 appears to have a good overall performance in the population studied here, as assessed by a similar discriminative performance (as assessed using the c-statistic) as in the original (2008) population. However, the 2008 score was less sensitive (but more specific) for prediction of mortality than a new score specifically derived from data of the studied population and additionally integrating cardiac comorbidities (which were not consistently recorded in the original –2008– population). Therefore, since the main purpose of such score should be to identify as much at-risk patients as possible, the new version might be preferable, at least for a population of patients hospitalized in a medical ward for an acute COPD exacerbation.

Strengths and limitations, applicability of results

One important strength of this study is that collected data were those usually available immediately at presentation in patients with exacerbations of COPD, to ensure

Table 3 Mortality rates by categories of the 2008 score and the new score

Categories	2008 score		Tertiles	New score	
	Groups*	Deaths n (%)		Derivation cohort	Validation cohort
0-1 point	692 (37.9%)	5 (0.7%)	0 point	1 (0.3%)	0 (0%)
2-3 points	672 (36.8%)	11 (1.6%)	1-2 points	4 (1.3%)	5 (1.6%)
4-6 points	460 (25.2%)	29 (6.3%)	3-9 points	18 (5.8%)	17 (5.5%)

*defined with reference to the distribution (i.e., tertiles) of the 2008 score in the 2008 population. The new score was built using data collected in the studied population.

Table 4 Performance of the scores in the present population (95% CI)

	2008 score		New score	
c-statistic	0.77	(0.72-0.81)	0.79	(0.74-0.82)
Sensitivity	0.64	(0.48-0.78)	0.77	(0.61-0.86)
Specificity	0.76	(0.74-0.78)	0.67	(0.65-0.69)

that the study conditions reflected what happens in the real-life. Actually, FEV₁ or arterial blood gas tensions did not add anything to the purely clinical variables that constituted both the 2008 score and the new score. We did not include any biomarker in the assessment of studied patients, since these variables might not be available in all settings yet nor immediately at patients' entry, which could limit the generalizability of a score relying on them. Indeed, variables of interest were collected rather exhaustively; however, this would have been quite different outside of a clinical survey (see below). Most scores developed in patients with AECOPD actually rely on some biological variables [4,5]. Even if these variables are available in most settings, this may increase the delay between arrival in the ED and risk stratification and, therefore, decisions regarding patients' orientation. Another strength is that two methods of development and validation of the new score were used, with identical results. This is reassuring as to the robustness of this score.

Some limitations also have to be considered when interpreting the results. Firstly, this study was performed in patients admitted to a medical respiratory ward for AECOPD, whatever their care pathway had been before. Therefore, although these patients were otherwise unselected, they are not representative of patients visiting Emergency Departments of admitted in Intensive Care Units or in non-specialized (e.g., internal medicine) wards. Indeed, the main purpose of these analyses was not to build a new score to be applied in a specific population, but to determine whether a score originally developed in patients visiting EDs could be applied in other settings

Table 5 Results of multiple logistic regression identifying factors independently associated with mortality in the studied population

	Odds-Ratio	95% CI	P value
Age (per year)	1,06	1,02-1,10	0,002
mMRC grade > 2 vs 0-1	3,91	1,70-8,96	0,001
Cardiovascular comorbidity (IHD and/of LHF)	2,28	1,06-4,91	0,036
Clinical signs of severity during the first 24 hours (per sign)*	1,34	1,18-1,53	<0,001

IHD : Ischemic heart disease; *LHF*: Left heart failure. *among the following: use of accessory inspiratory muscles, asterix, neurological impairment, paradoxical abdominal movement, lower limb edema, cyanosis.

Table 6 Calculation of the new score, based on results of multivariate analysis of factors associated with in-hospital death in the studied population

New score	Points
Age	
• < 60 years	0
• 60-80 years	1
• 80 years	2
MRC (baseline, steady state)	
• 0-2	0
• > 2	3
Cardiovascular disease	
• No	0
• Yes	2
Number of signs of severity (first 24 hours)	
• 0	0
• 1-2	1
• 3 and more	2

Range of the total score: 0-9.

with satisfactory properties. Secondly, patients recruited in a medical ward are by nature those who have survived the first step of care for their exacerbation, e.g. the ED care. Indeed, in our 2008 study, 10 patients died in the ED (1.25%) and 7 (0.9%) died in the ICU in which they had been transferred from the ED [9]. Overall, 28,8% of all in-hospital deaths observed in that study occurred before the patient could reach the medical ward, and would therefore not have been captured in the present study.

Variables included in the 2008 score and the new score

Besides differences in the weighting of some variables, the main difference between the two scores was that the new one accounted for cardio-vascular major comorbidities, i.e., IHD and LHF. This is likely explained by the lack of details on cardio-vascular comorbidities in the 2008 population, obviously preventing them from being reliably included in the score calculation. All other contributing variables (i.e., age, baseline mMRC grade at steady state and number of clinical signs of severity at entry) were the same, which confirms the strength of their association with mortality. This underlines the major importance of recording them at entry, which is not always done. Indeed, an audit in UK hospitals found marked heterogeneity of variables recorded in patients hospitalized for AECOPDs [14]. The European Respiratory Society audit on AECOPDs also found noticeable discrepancies between settings and countries in the way AECOPDs are assessed and cared for [15]. Whether this translates in differences in outcomes or cost-effectiveness of care remains to be demonstrated.

Interestingly, the importance of cardio-vascular comorbidities as prognostic factors in AECOPD is in line with the high proportion of cardiovascular deaths in patients with COPD [16,17]. Indeed, cardiovascular comorbidities are frequent in these patients [18,19], due to common risk factors (smoking, age) and maybe also to specific pathophysiological mechanisms involving COPD-associated systemic inflammation [20–22]. COPD is also known to impair the prognosis of cardiovascular diseases such as IHD or CHF [23,24] while a low FEV1 increases the risk of atheroma [25] and cardiovascular death [26]. In addition, ischemic cardiovascular events are frequent during and early after AECOPD [27,28].

Is the use of a score able to improve outcomes of AECOPD?

In the field of AECOPD outside ICUs, it has never been demonstrated that using such a score has an effect on the appropriateness of medical decisions. In other acute respiratory diseases such as community acquired pneumonia (CAP), the use of scores (e.g. the Pneumonia Severity Index) was shown to improve the efficiency of patients orientation through a decrease in hospitalizations without any increase in the risk of poor outcome [7]. However, it might be argued that AECOPD and CAP are conceptually very different diseases: CAP are by definition of infectious origin while only about 50% of AECOPD are associated with identification of a pathogen [1]. In AECOPD, the main phenomenon is not parenchymal infection but airways obstruction. In addition, in AECOPD other etiologies of respiratory failure such as pulmonary embolism are frequent and frequently undiagnosed [29]. Thus, it could be hypothesized that building a simple clinical score would be more difficult in AECOPD, due to their marked heterogeneity. However, the scores we developed are not more complex than, e.g., the CRB-65. Conversely, in a recent study, Steer et al. developed a score called the DECAF score, relying on extended MRC Dyspnoea Score, eosinopenia, consolidation, acidaemia, and atrial fibrillation [5]. Using internal bootstrap validation, the score predicted mortality quite reliably, with an area under the receiver operator characteristic (ROC) curve of 0.86. In addition, the DECAF score was a significantly stronger predictor of mortality than CURB-65. However, this score relies not only on clinical features but also on some radiological and biological characteristics, which might limit its applicability for use at entry in the ED. Besides the variables included in these scores, several other clinical, biological or radiological data have been found to be of prognostic significance in AECOPD (regarding, e.g., the risks of death, need for mechanical ventilation or prolonged hospitalization) [3]. Adding biological or imaging variables might improve the predictive capacity of the scoring systems but, as mentioned above, this would

compromise their use in the community setting and, even in the hospital, awaiting their results could delay the score-based decisions.

Interestingly, although the DECAF score comprises three non-clinical (i.e., biological or radiological) variables, the area under the ROC curve (0.86) in its development study was not considerably superior to that of our purely clinical score (0.79). Of note, the c-statistic of the BAP-65 score (which uses one biological variable, BUN) in the validation study by Shorr et al. was also 0.79 [30].

Conclusions

In this study, we confirm in hospitalized patients the overall good predictive properties of a purely clinical score initially developed in patients visiting the ED for an AECOPD. Adding major cardiac comorbidities (IHD, LHF) to scoring items increased the sensitivity of the score for mortality prediction. Additional studies are required to determine whether the use of such scores increases the efficiency of care for AECOPD, both in hospital or community settings.

Additional file

Additional file 1: Supplementary methods and tables: case by case score development and univariate analyzes.

Abbreviations

ANOVA: Analysis of variance; COPD: Chronic obstructive pulmonary disease; CPHG: French College of General Hospital Respiratory Physicians; FEV1: Forced expiratory volume in one second; GOLD: Global Initiative for Chronic Obstructive Lung Disease; ICU: Intensive care unit; MRC: Medical Research Council; OR: Odds ratio.

Competing interests

NR received fees for speaking, organizing education or consulting from Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MEDA, MSD, Mundipharma, Novartis, Nycomed, Pfizer, and Teva; and research funds from Boehringer Ingelheim, Novartis, Nycomed, Pfizer.

JP received fees for speaking or consulting from AstraZeneca, GlaxoSmithKline and Nycomed.

JMC received fees for speaking or consulting from AstraZeneca, Novartis.

CM received fees for speaking or consulting from GlaxoSmithKline and Novartis.

MZ has no conflict of interest in relation to this article.

Authors' contributions

All authors participated to the design of analyses, interpretation of results and discussion of the manuscript content. NR initiated the project and drafted the first and revised versions, statistics were performed by MZ, JP coordinated the cohort project. All authors read and approved the final manuscript.

Acknowledgments

The present analyses were funded by Boehringer Ingelheim France. The cohort was funded by the French College of General Hospital Respiratory Physicians (CPHG); the French Directorate General of Health Services (DGS), the French Federation of Pneumology (FFP), the French-Language Society of Pneumology (SPLF), the French National Committee against Respiratory Diseases (CNMR); Astra-Zeneca; Boehringer Ingelheim-Pfizer; Glaxo-Smith-Kline; Orkyn; Pneumologie développement; and Vitalaire.

The authors also like to thank all the lung specialists who have actively participated in this study:

Drs Olivier Chrétien, Alençon; Toufik Didi, Annecy; Jean-Michel Chavaillon, Antibes; Juliette Camuset, Argenteuil; Patrick Brunet, Arpajon; Jean-Pierre Orlando, Aubagne; Pierre Pasquer, Aurillac; Philippe Tagu, Bar-le-Duc; Jean-Pierre Mathieu, Bayonne; Michel Mornet, Bourges; Denis Braun, Briey; François Viau, Briis-sous-Forges - Bligny; Patricia Barré, Cahors; Philippe Carré, Carcassonne; Gérard Body, Chalons-en-Champagne; Eric Kelkel, Chambéry; Marguerite Le Poulain-Doubliez, Charleville-Mézières; Charles Sleiman, Chartres; Francis Martin, Compiègne; Odile Salmon, Corbeil-Essonnes; Cyril Bernier, Dinan; Edith Maetz, Douai; Jean-Renaud Barrière, Draguignan; Mourad Grib, Dreux; Christian Delafosse, Eaubonne; Philippe David, Elbeuf; Michel Carbonnelle, Epernay; Jean-Louis Collignon, Epinal; Guillaume Fesq, Evreux; Béatrice Desurmont Salasc, Fréjus; Laetitia Chemery, Granville; Philippe Bonnefoy, Jonzac; Jean-Robert Calvaire, Le Carbet - Martinique; Cécile Dujon, Le Chesnay Versailles; Gilles Gonzalez, Le Creusot; Jean Queiffin, Le Havre; François-Xavier Lebas et François Goupil, Le Mans; Michel Marcos, Libourne; Gérard Oliviero, Longjumeau; Bernard Duvert, Lons-le-Saunier; Hervé Jullian, Martigues; François Blanchon et Laurence Moncelly, Meaux; Bruno Caillet, Montélimar; Jacques Piquet et Cyril Maurer, Montfermeil; Guillaume Foulon, Nanterre; Corinne Lamour, Niort; Pablo Ferrer Lopez, Papeete - Polynésie Française; Laurence Marsal et Nicolas Roche, Hôtel-Dieu, Paris; Marie Bénichou, Pau; Serge Lacroix, Périgueux; François Sénéchal, Pontoise; Henri Barbieux et Nicolas Just, Roubaix; Daniel Acker, Saint-Avold; Daniel Coëtmeur, Saint-Brieuc; Bernard Tanguy, Saint-Denis - La Réunion; Christophe Roy, Sainte-Foy-la-Grande; Perrine Hermant, Saint-Germain-en-Laye; Hugues Morel, Saint-Malo; Michel Martin, Saint-Michel; Amer Karimo, Saint-Omer; Claude Arvin-Berod, Saint-Pierre - La Réunion; Marie-Germaine Legrand-Hougnon, Soissons; Alain Béraud, Thionville; Dominique Andreotti et Bruno Escarguel, Toulon; Céline Louerat, Valence; Didier Debieuvre, Vesoul; Catherine Fouret, Villeneuve-Saint-Georges; Hassane Ziani Bey, Vire; Alain Strecker, Wattrelos.

Author details

¹Respiratory and Intensive Care Medicine department, Cochin Hospital Group, APHP, University Paris Descartes (EA2511), 75005 Paris, France.

²Respiratory medicine and intensive care department, Antibes General Hospital, 06606 Antibes-Juan les Pins, France. ³Respiratory medicine department, Le Raincy-Montfermeil hospital, 93370 Montfermeil, France.

⁴INSERM Unit 700, Xavier Bichat University, 75018 Paris, France.

Received: 23 December 2013 Accepted: 13 August 2014

Published: 27 August 2014

References

1. Wedzicha JA, Seemungal TAR: COPD exacerbations: defining their cause and prevention. *Lancet* 2007, **370**:786–796.
2. Jeppesen E, Brurberg KG, Vist GE, Wedzicha JA, Wright JJ, Greenstone M, Walters JAE: Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2012, **5**, CD003573.
3. Roche N, Rabbat A, Zureik M, Huchon G: Chronic obstructive pulmonary disease exacerbations in emergency departments: predictors of outcome. *Curr Opin Pulm Med* 2010, **16**:112–117.
4. Shorr AF, Sun X, Johannes RS, Derby KG, Tabak YP: Predicting the need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: comparing the CURB-65 and BAP-65 scores. *J Crit Care* 2012, **27**:564–570.
5. Steer J, Gibson J, Bourke SC: The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. *Thorax* 2012, **67**:970–976.
6. Stolz D, Christ-Crain M, Morgenthaler NG, Miedinger D, Leuppi J, Müller C, Bingisser R, Struck J, Müller B, Tamm M: Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. *Chest* 2008, **134**:263–272.
7. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997, **336**:243–250.
8. Roche N, Zureik M, Soussan D, Neukirch F, Perrotin D: Predictors of outcomes in COPD exacerbation cases presenting to the emergency department. *Eur Respir J* 2008, **32**:953–961.

9. Piquet J, Chavaillon J-M, David P, Martin F, Blanchon F, Roche N: High-risk patients following hospitalisation for an acute exacerbation of COPD. *Eur Respir J* 2013, **42**:946–955.
10. Chavaillon J-M, Leroisseau L, David P, Martin F, Lamour C, Beraud A, Sleiman C, Debieuvre D, Just N, Senechal F, Camuset J, Mornet M, Fesq G, Zureik M, Roche N, Blanchon F, Piquet J: Intrahospital mortality during acute exacerbations of COPD. study EABPCO-CPHG of the College of the Lung specialists of General hospitals (CPHG). *Rev Mal Respir* 2010, **27**:709–716.
11. Concato J, Feinstein AR, Holford TR: The risk of determining risk with multivariable models. *Ann Intern Med* 1993, **118**:201–210.
12. Walter LC, Brand RJ, Counsell SR, Palmer RM, Landefeld CS, Fortinsky RH, Covinsky KE: Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. *JAMA* 2001, **285**:2987–2994.
13. Lee SJ, Lindquist K, Segal MR, Covinsky KE: Development and validation of a prognostic index for 4-year mortality in older adults. *JAMA* 2006, **295**:801–808.
14. Roberts CM, Ryland I, Lowe D, Kelly Y, Bucknall CE, Pearson MG: Audit of acute admissions of COPD: standards of care and management in the hospital setting. Audit Sub-committee of the Standards of Care Committee of the British Thoracic Society and the Clinical Effectiveness and Evaluation Unit at the Royal College of Physicians. *Eur Respir J* 2001, **17**:343–349.
15. Roberts CM, Lopez-Campos JL, Pozo-Rodriguez F, Hartl S, European COPD Audit team: European hospital adherence to GOLD recommendations for chronic obstructive pulmonary disease (COPD) exacerbation admissions. *Thorax* 2013, **68**:1169–1171.
16. Huiart L, Ernst P, Suissa S: Cardiovascular morbidity and mortality in COPD. *Chest* 2005, **128**:2640–2646.
17. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J: Cardiovascular events in patients with COPD: TORCH study results. *Thorax* 2010, **65**:719–725.
18. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, She D: Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. *Ann Epidemiol* 2006, **16**:63–70.
19. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, Fabbri LM, Clini EM: Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. *Thorax* 2008, **63**:487–492.
20. Sin DD, Man SF: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? the potential role of systemic inflammation in chronic obstructive pulmonary disease. *Circulation* 2003, **107**:1514–1519.
21. Ghoorah K, De Soya A, Kunadian V: Increased cardiovascular risk in patients with chronic obstructive pulmonary disease and the potential mechanisms linking the two conditions: a review. *Cardiol Rev* 2012, **21**:196–202.
22. Man SFP, Van Eeden S, Sin DD: Vascular risk in chronic obstructive pulmonary disease: role of inflammation and other mediators. *Can J Cardiol* 2012, **28**:653–661.
23. Aboufakher R, Riba A, Jani SM, Goswami R, Schwartz S, Lins S, Gardin J, Smith DE, Kline-Rogers E, Share D, Moscucci M: Incidence, risk factors, and prognosis of inhospital heart failure after percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). *Am Heart J* 2005, **150**:455–458.
24. Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG, McMurray JJV: Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. *Eur J Heart Fail* 2009, **11**:684–690.
25. Zureik M, Benetos A, Neukirch C, Courbon D, Bean K, Thomas F, Ducimetiere P: Reduced pulmonary function is associated with central arterial stiffness in men. *Am J Respir Crit Care Med* 2001, **164**:2181–2185.
26. Sin DD, Wu L, Man SF: The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. *Chest* 2005, **127**:1952–1959.
27. McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R, O'Connor J, McAlpine L, Chalmers G, Newby DE, Clark E, Macfarlane PW, Macnee W: Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. *Eur Respir J* 2012, **39**:1097–1103.

28. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA: **Increased risk of myocardial infarction and stroke following exacerbation of COPD.** *Chest* 2010, **137**:1091–1097.
29. Rizkallah J, Man SFP, Sin DD: **Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis.** *Chest* 2009, **135**:786–793.
30. Shorr AF, Sun X, Johannes RS, Yaitanes A, Tabak YP: **Validation of a novel risk score for severity of illness in acute exacerbations of COPD.** *Chest* 2011, **140**:1177–1183.

doi:10.1186/s12931-014-0099-9

Cite this article as: Roche *et al.*: A clinical in-hospital prognostic score for acute exacerbations of COPD. *Respiratory Research* 2014 **15**:99.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

